Trial Profile
A Phase 1b, Dose-escalation Study to Evaluate the Safety, Tolerability, and the Lymphocyte Increasing Effects of GX-I7 Intramuscular Administration in Patients With Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Genexine
- 08 Nov 2020 Status changed from active, no longer recruiting to completed.
- 30 Mar 2020 Planned End Date changed from 14 May 2020 to 31 Mar 2021.
- 30 Mar 2020 Planned primary completion date changed from 14 Feb 2020 to 31 Jan 2021.